Aeterna Zentaris Inc. announced it has begun promoting APIFINY, the only non-PSA blood test for the evaluation of prostate cancer risk, in the U.S. under a co-marketing agreement with Armune BioScience, Inc. Under the agreement, Zentaris will promote APIFINY to designated medical professionals in 20 American territories, and receive a commission for each test that results from its promotion, the company says in its press release.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?